Charles River Laboratories | CRL - Fremdkapital

Aktienkurs
178.34
Täglich Wechseln
2.69 1.53%
Monatlich
17.35%
Jährlich
67.30%
Q2 Prognose
170.85




Fremdkapital Veränderung Datum
Agilent USD 3.05B 0 2025-12
Align Technology USD 0 0 2024-12
Bio-Rad Laboratories USD 1.2B 300K 2025-12
Bruker USD 1.85B 131.7M 2025-12
Cardinal Health USD 8.35B 633M 2025-12
Charles River Laboratories USD 2.14B 49.09M 2025-12
Cigna USD 30.95B 4.47B 2025-09
Concord Medical Services Hldg CNY 2.27B 3.79M 2025-06
CVS Health USD 60.5B 6M 2025-12
Danaher USD 18.42B 1.58B 2025-12
Dentsply International USD 2.02B 2M 2025-12
Elevance Health USD 30.8B 376M 2025-12
Galapagos EUR 5.19M 574K 2025-12
Hologic USD 2.5B 2.1M 2025-12
Humana USD 12.37B 238M 2025-12
Illumina USD 1.49B 496M 2025-12
Incyte USD 30.2M 5.17M 2025-12
Intrexon USD 0 198.67M 2024-06
IQVIA Holdings USD 13.88B 1.09B 2025-12
Laboratory Of America USD 5.15B 800K 2025-12
Lonza CHF 3.88B 323M 2025-12
McKesson USD 5.43B 586M 2025-12
Merck EUR 10.73B 277M 2025-12
Mettler Toledo International USD 2.09B 58.01M 2025-12
Novartis USD 29.59B 5.35B 2025-12
Pfizer USD 57.41B 93M 2025-09
Quest Diagnostics USD 5.17B 4M 2025-12
Revvity USD 2.63B 543K 2025-12
Thermo Fisher Scientific USD 35.85B 4B 2025-12
United Therapeutics USD 100M 100M 2024-06
UnitedHealth USD 72.32B 79M 2025-12
Veradigm USD 200.4M 69K 2022-12
Waters USD 1.41B 460.24M 2025-12
West Pharmaceutical Services USD 202.8M 100K 2025-12